PM 226

Discontinued Product

PM 226 (Cat. No. 6220) has been withdrawn from sale for commercial reasons.
Cat.No. 6220 - PM 226 | C22H31NO3 | CAS No. 1949726-13-9
Description: Potent and selective CB2 receptor agonist; BBB permeable; neuroprotective
Chemical Name: 7-(1,1-Dimethylheptyl)-9-methoxy-4,4-dimethyl-4H-[1]benzopyrano[3,4-d]isoxazole
Purity: ≥98% (HPLC)
Literature (5)

Biological Activity for PM 226

PM 226 is a potent and selective CB2 receptor agonist (Ki = 12.8 nM; EC50 = 38.67 nM). Exhibits negligible affinity for the CB1 receptor (Ki > 40,000 nM) and no activity at the GPR55. Suppresses neuroinflammation by reducing microglial activation in a multiple sclerosis mouse model. BBB permeable; anti-inflammatory and neuroprotective.

Technical Data for PM 226

M. Wt 357.49
Formula C22H31NO3
Storage Store at -20°C
Purity ≥98% (HPLC)
CAS Number 1949726-13-9
PubChem ID 132510986
Smiles CCCCCCC(C)(C1=CC(OC)=C2C3=C(C(C)(OC2=C1)C)C=NO3)C

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

References for PM 226

References are publications that support the biological activity of the product.

Navarro et al (2016) Targeting cannabinoid CB2 receptors in the central nervous system. Medicinal chemistry approaches with focus on neurodegenerative disorders. Front. Neurosci. 10 406 PMID: 27679556

Morales et al (2016) Chromenopyrazole, a versatile cannabinoid scaffold with in vivo activity in a model of multiple sclerosis. J.Med.Chem. 59 6753 PMID: 27309150

Gómez-Cañas et al (2016) Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile. Pharmacol.Res. 110 205 PMID: 27013280

View Related Products by Target

View Related Products by Product Action

View all CB2 Receptor Agonists

Keywords: PM 226, PM 226 supplier, PM226, Potent, selective, CB2, agonists, agonism, BBB, permeable, anti-inflammatory, neuroprotective, cannabinoids, receptors, Receptors, 6220, Tocris Bioscience

Citations for PM 226

Citations are publications that use Tocris products.

Currently there are no citations for PM 226.

Reviews for PM 226

There are currently no reviews for this product. Be the first to review PM 226 and earn rewards!

Have you used PM 226?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

GPCR Product Listing

GPCR Product Listing

A collection of over 450 products for G protein-coupled receptors, the listing includes research tools for the study of:

  • Rhodopsin-like Receptors
  • Glutamate Receptors
  • Frizzled Receptors
  • GPCR Signaling
Neurodegeneration Product Guide

Neurodegeneration Product Guide

A collection of over 275 products for neurodegeneration research, the guide includes research tools for the study of:

  • Alzheimer's disease
  • Parkinson's disease
  • Huntington's disease
Pain Research Product Guide

Pain Research Product Guide

A collection of over 280 products for pain research, the guide includes research tools for the study of:

  • Nociception
  • Ion Channels
  • G-Protein-Coupled Receptors
  • Intracellular Signaling
Cannabinoid Receptor Ligands Scientific Review

Cannabinoid Receptor Ligands Scientific Review

Written by Roger Pertwee, this review discusses compounds which affect the activity of the endocannabinoid system, focusing particularly on ligands that are most widely used as experimental tools and denotes compounds available from Tocris.

Epilepsy Poster

Epilepsy Poster

Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.